<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82017">
  <stage>Registered</stage>
  <submitdate>12/05/2007</submitdate>
  <approvaldate>15/05/2007</approvaldate>
  <actrnumber>ACTRN12607000260426</actrnumber>
  <trial_identification>
    <studytitle>A Phase 1 Single-Center, Open-Label Study to Evaluate the Safety and Pharmacokinetics of a Candidate Topical Antimicrobial (NEO101) among Healthy Adult Men</studytitle>
    <scientifictitle>A Phase 1 Single-Center, Open-Label Study to Evaluate the Safety and Pharmacokinetics of a Candidate Topical Antimicrobial (NEO101) among Healthy Adult Men</scientifictitle>
    <utrn />
    <trialacronym>NEO101-CLIN-N002</trialacronym>
    <secondaryid>Therapeutic Goods Association Clinical Trial Notification (TGA CTN): YGA CTN - 2007/247 (issued on 03/05/07)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Open-label safety pharmacokinetic study in healthy adult men of topical antimicrobial being developed for the indication of nasal carriage of Staphylococcus aureus.</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>On Day 1 and Day 7 subjects will receive a single topical application of NEO101 to each nostril. On Day 4 through Day 6 subjects will receive a treatment course of three-times-daily topical application of NEO101 to each nostril.  Each application consists of 0.1mL 0.95% NEO101 per nostril.  Pharmacokinetic blood sampling will be done on Days 1, 4-7, 8 and 10.  Safety evaluations will be performed during the treatment course and for 14 days following treatment.</interventions>
    <comparator>No comparator/control treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective of this study is to evaluate the safety, including pharmacokinetic monitoring, of three-times-daily topical nasal application of NEO101 for 3 days among healthy adult men.</outcome>
      <timepoint>Pharmacokinetic blood sampling will be done on Days 1, 4-7, 8 and 10.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None.</outcome>
      <timepoint>None.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects, in general good health, compliant with (defined) birth control.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug, have clinical evidence of active cutaneous infection, have had skin or soft tissue infection with S. aureus within 30 days prior to enrollment, have documented disruption of the nasal or facial bones, have atopic dermatitis/eczema, allergic rhinitis, nasal polyps or nasal piercings, have a history of hypersensitivity or allergic reactions to parabens, sodium sulfite or any other ingredient in the formulation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>14/05/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>5</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Neosil, Inc</primarysponsorname>
    <primarysponsoraddress>5980 Horton Street, Suite 525
Emeryville, California 94608</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Neosil, Inc</fundingname>
      <fundingaddress>5980 Horton Street, Suite 525
Emeryville, California 94608</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety, including blood sampling for pharmacokinetic monitoring, of a new topical anti-infective (NEO101) applied to each nostril.  A single dose will be applied on Day 1 and Day 7 of the study, and three-times-daily doses will be applied on Days 4, 5 and 6.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Q-Pharm Pty Ltd, Clive Berghofer Cancer Research Center-Queensland Institute of Medical Research Human Research Ethics Committee</ethicname>
      <ethicaddress>300 C Herston Road, Herston, Queensland 4006</ethicaddress>
      <ethicapprovaldate>3/05/2007</ethicapprovaldate>
      <hrec>2007/247 </hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andria Langenberg, MD</name>
      <address>Neosil Inc.
5980 Horton Street
Suite 525
Emeryville California  94608</address>
      <phone>+1 510 547 3610, ext 180</phone>
      <fax>+1 510 547 3604</fax>
      <email>andria.langenberg@neosil.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Suzanne Elliott, Operations Manager</name>
      <address>Q-Pharm Pty Ltd
PO Box 78
Royal Brisbane Hospital
Brisbane, Queensland 4029</address>
      <phone>+61 7 38453644</phone>
      <fax>+61 7 38453637</fax>
      <email>s.elliott@qpharm.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Michael McKown</name>
      <address>Neosil, Inc.
5980 Horton Street, Suite 525
Emeryville, California 94608</address>
      <phone>+1 510 547 3610, ext 180</phone>
      <fax>+1 510 547 3604</fax>
      <email>michael.mckown@neosil.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>